Evidence map›Paper›PMID 24734906›Full record

ArticleExpert review of clinical immunology2014

The potential of radioimmunotherapy as a new hope for HIV patients.

Dina Tsukrov, Ekaterina Dadachova

Open access · greenAbstract readEditorial
In one paragraph

Article in Expert review of clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Dina TsukrovDepartments of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA.
Ekaterina Dadachova
Albert Einstein College of Medicine · US

Funding

Clinical and Translational Science Award (UL1)UL1TR000086 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SHAMOON, HARRY · 2012 to 2013
$5.5M
Clinical and Translational Science AwardTL1TR001072 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI SHAMOON, HARRY · 2013 to 2017
$909k
NCATS NIH HHS 8UL1 TR000086NCATS NIH HHS TL1 TR001072NCATS NIH HHS UL1 TR000086
6 · The paper itself

Abstract

HIV/AIDS remains an enormous public health burden. Advances in anti-retroviral therapy (ART) have greatly reduced mortality and morbidity but HIV remains incurable, with patients suffering numerous disease- and treatment-related side effects. Any curative strategy for HIV must selectively eliminate existing infected cells. Radioimmunotherapy (RIT) is an established clinical modality in cancer treatment and has been shown to be effective in multiple infectious diseases models. We have recently demonstrated that RIT using a gp41-targeting antibody was effective and safe in eliminating HIV-infected cells in vivo (in mice), in vitro, and ex vivo in cells from HIV patients treated with ART. In addition, there is strong evidence that this radiolabeled antibody can eliminate HIV infected cells across the blood brain barrier. We consider RIT to be the most promising backbone strategy for HIV eradication.

Indexed as

AnimalsAnti-Retroviral AgentsCombined Modality TherapyHIV InfectionsHumansMiceRadioimmunotherapyReproducibility of ResultsAnti-Retroviral Agents

Identifiers

PMID24734906
PMCPMC4086790
OpenAlexW1970523182

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.